| Patients | P* < 0.001 | R | P# | ||
---|---|---|---|---|---|---|
All (n = 107) | MBL low 319 < ng/mL (n = 26) | MBL high 319 ≥ ng/mL (n = 81) | ||||
MBL range (ng/mL) | 821 [319–1477] | 98 [33–146] | 1290 [671–1848] | |||
Demographics | ||||||
Age, years | 62.5 ± 15.6 | 65.3 ± 12.1 | 61.56 ± 16.6 | 0.3 | −0.26 | 0.007 |
Male gender, n (%) | 71 (66) | 17 (65) | 54 (67) | 1.0 | Â | Â |
Current diabetes, n (%) | 25 (24) | 9 (35) | 16 (20) | 0.2 | Â | Â |
Hypertension, n (%) | 85 (84) | 22 (88) | 63 (83) | 0.8 | Â | Â |
Cardiovascular history, n (%) | 26 (25) | 9 (35) | 15 (19) | 0.1 | Â | Â |
BMI, kg/m2 | 25.8 ± 4.4 | 27.0 ± 4.5 | 25.4 ± 4.4 | 0.1 | −0.03 | 0.8 |
Hemodialysis | ||||||
Dialysis vintage, months | 25.5 [8.5–52.3] | 18.2 [7.0–47.7] | 32.8 [9.1–53.3] | 0.2 | −0.01 | 0.9 |
Primary renal disease, n (%) | ||||||
Hypertension | 18 (17) | 4 (15) | 14 (17) | 1.0 | Â | Â |
Diabetes | 14 (13) | 5 (19) | 9 (11) | 0.3 | Â | Â |
ADPKD | 13 (12) | 3 (12) | 10 (12) | 1.0 | Â | Â |
FSGS | 9 (8) | 4 (15) | 5 (6) | 0.2 | Â | Â |
IgA nephropathy | 4 (4) | 0 (0) | 4 (5) | 0.6 | Â | Â |
Chronic pyelonephritis | 3 (3) | 0 (0) | 3 (4) | 1.0 | Â | Â |
Glomerulonephritis | 13 (12) | 2 (8) | 11 (14) | 0.7 | Â | Â |
Other diagnoses | 16 (16) | 6 (23) | 10 (12) | 0.2 | Â | Â |
Unknown | 17 (16) | 2 (8) | 15 (19) | 0.2 | Â | Â |
Ultrafiltration volume, L | 2.55 ± 0.78 | 2.54 ± 0.82 | 2.56 ± 0.78 | 0.9 | −0.01 | 0.9 |
Ultrafiltration rate, mL/kg/h | 8.56 ± 2.63 | 7.81 ± 2.39 | 8.80 ± 2.67 | 0.1 | 0.04 | 0.7 |
Systolic blood pressure | ||||||
Predialysis, mmHg | 140.4 ± 25.1 | 144.7 ± 26.4 | 139.1 ± 24.7 | 0.3 | −0.17 | 0.08 |
Postdialysis, mmHg | 131.8 ± 25.6 | 136 ± 24.3 | 130.4 ± 26.0 | 0.4 | −0.24 | 0.02 |
Heart rate | ||||||
Predialysis, bpm | 73 [63–82] | 71 [62–82] | 74 [64–82] | 0.3 | 0.11 | 0.3 |
Postdialysis, bpm | 79 [69–87] | 75 [65–86] | 79 [69–88] | 0.4 | 0.13 | 0.2 |
Kidney transplant, n (%) | 21 (20) | 4 (15) | 17 (21) | 0.8 | Â | Â |
Laboratory measurements | ||||||
Hematocrit, % | 34.9 ± 3.8 | 34.5 ± 4.1 | 35.0 ± 3.7 | 0.6 | 0.04 | 0.7 |
HbAlc, mmol/mol | 5.68 ± 0.98 | 5.80 ± 0.97 | 5.63 ± 0.98 | 0.5 | −0.15 | 0.2 |
Albumin, g/L | 39 [37–42] | 39 [37–42] | 39 [37–42] | 0.9 | 0.01 | 0.9 |
pH | 7.37 [7.34–7.39] | 7.37 [7.32–7.39] | 7.37 [7.34–7.39] | 0.7 | 0.05 | 0.6 |
Calcium, mmol/L | 2.31 ± 0.16 | 2.31 ± 0.15 | 2.32 ± 0.16 | 0.9 | 0.03 | 0.7 |
Phosphate, mmol/L | 1.67 ± 0.53 | 1.82 ± 0.47 | 1.65 ± 0.54 | 0.2 | −0.00 | 0.9 |
hsCRP, mg/L | 6.7 [2.8–10.9] | 6.1 [1.4–12.0] | 6.7 [3.0–10.9] | 0.7 | 0.10 | 0.3 |
Medication | ||||||
Aspirin, n (%) | 57 (54) | 11 (42) | 46 (64) | 0.3 | Â | Â |
Calcium channel blockers, n (%) | 14 (13) | 3 (12) | 11 (14) | 1.0 | Â | Â |
β-Blocker, n (%) | 61 (57) | 18 (69) | 43 (53) | 0.2 |  |  |
ACE inhibitor, n (%) | 10 (10) | 3 (12) | 7 (9) | 0.7 | Â | Â |
AT2-receptor antagonists, n (%) | 14 (13) | 2 (8) | 12 (15) | 0.5 | Â | Â |
Statin, n (%) | 20 (19) | 5 (19) | 15 (19) | 1.0 | Â | Â |
Diuretics, n (%) | 8 (8) | 3 (12) | 5 (6) | 0.4 | Â | Â |